ERBB2 and neoplasm: In contrast, patients with luminal-B, triple-negative, or trastuzumab-untreated HER2-positive tumors showed decreased DFS because of delayed chemotherapy, highlighting the importance of timely initiation of chemotherapy in aggressive tumor subtypes.